- Veeva Systems delivers 17% revenue growth at 38% operating margins — a rare combination in healthcare SaaS
- Tempus AI (IPO June 2024) has $700M+ annualized revenue growing 25% with a 1,000+ hospital network
- Radiology AI (Nuance, Rad AI, Aidoc) is the fastest-growing AI healthcare application with FDA clearances accelerating
- Best risk/reward: Veeva at 30x earnings — high quality, durable moat, clinical AI adoption tailwind
Section 1 — Healthcare AI: Where Science Meets Commercial Reality
Healthcare is the sector where AI has moved most rapidly from laboratory promise to regulated commercial deployment. Unlike consumer AI applications where deployment is limited only by cost and adoption, healthcare AI products require FDA clearance or regulatory approval — creating a slower but more durable competitive advantage for first movers.
The FDA's Digital Health Center of Excellence cleared 692 AI/ML-based medical devices through the end of 2025, up from 222 in 2021. The acceleration reflects both improved AI capabilities and a regulatory learning process: the FDA has developed standardized evaluation frameworks for AI diagnostic devices that have reduced approval timelines from 18-24 months to 8-12 months for well-characterized device types (radiology screening, ECG interpretation, drug interaction flagging).
The global healthcare AI market is estimated at $22.4 billion in 2025 and is projected to reach $67.1 billion by 2030 (24.5% CAGR). The growth drivers are distribution across four subsectors: diagnostics and imaging ($8.2B), drug discovery and development ($6.1B), clinical operations and data management ($5.4B), and patient monitoring and personalized medicine ($2.7B). Each subsector has distinct competitive dynamics and investment implications.
For investors, the key distinction is between healthcare IT companies that are adding AI features to existing platforms (Veeva, Epic, Oracle Health) and pure-play healthcare AI companies that are building AI-native products for clinical workflows (Tempus, Recursion, Insilico). The former have established distribution and customer relationships but face "AI-washing" skepticism; the latter have genuine AI differentiation but unproven commercial scale.
Section 2 — Veeva vs. Competitors: The Clinical Data Platform Battle
Veeva Systems occupies a uniquely enviable competitive position. The company provides cloud-based software to pharmaceutical and biotech companies for regulatory compliance, clinical data management, and medical affairs. Its CRM (Salesforce vertical for pharma), Vault (document management for clinical trials), and the newer Veeva Data Cloud products serve 1,500+ pharma and biotech customers including all 50 of the world's largest pharmaceutical companies.
The AI opportunity for Veeva is additive to an already-excellent business. Veeva's Vault Clinical platform — which manages clinical trial data, patient records, and regulatory submissions — is positioned to add AI features that accelerate trial design, automate data monitoring, and flag safety signals. The Veeva AI partner ecosystem, launched in 2025, has signed 34 specialist AI companies to build within the Vault platform, creating a network effect that would take years for a competitor to replicate.
At 30x forward earnings for 17% revenue growth and 38% operating margins, Veeva is not cheap by traditional metrics but is reasonably priced for the quality of the business. The key risk is the ongoing Salesforce relationship transition: Veeva is mid-way through replacing Salesforce's CRM infrastructure with its own Veeva Vault CRM, and any technical issues in this migration could disrupt customer relationships.
IQVIA Holdings (IQV) is Veeva's main competitor in clinical data services, with $15.3B in 2025 revenue and a more diverse business model that includes contract research organization (CRO) services. IQVIA's Orchestrated Clinical Trials platform competes directly with Veeva Vault. At 18x forward earnings, IQVIA offers better value but lower growth and a more complex business to analyze.
| Company | Revenue '25 | Rev Growth | Fwd P/E |
|---|---|---|---|
| Veeva Systems (VEEV) | $2.3B | +17% YoY | 30x |
| IQVIA Holdings (IQV) | $15.3B | +8% YoY | 18x |
| Tempus AI (TEM) | ~$600M | +25% YoY | N/A (loss) |
| Medtronic AI unit (MDT) | ~$1.2B | +31% YoY | Embedded in MDT |
| Nuance (MSFT sub) | ~$2B | +28% YoY | Not standalone |
Section 3 — Tempus AI: The Oncology Data Play
Tempus AI went public at $37/share in June 2024 and had a bumpy first year as a public company. Revenue of $600M+ in 2025 is impressive, but the company lost $289M on an operating basis. The business model — sequencing cancer patient genomes at cost and monetizing the resulting data to pharma companies for drug trials — is compelling long-term but capital-intensive short-term. At 15x 2026 revenue, the stock prices in significant monetization acceleration.
Tempus AI represents one of the most intellectually interesting healthcare AI investments currently available. The company has built a network of 2,000+ oncologists and 1,000+ hospitals that use Tempus genomic sequencing for cancer diagnosis. Critically, with patient consent, Tempus aggregates this genomic, clinical, and outcomes data into what is now the largest structured oncology dataset in the world — 5 million+ de-identified patient records.
The business model is fundamentally about data monetization. Tempus charges oncologists a subsidized rate for genomic sequencing (roughly $1,500-2,000 per test, with the true sequencing cost running $3,000-4,000) and recoups the subsidy through data licensing fees from pharmaceutical companies running clinical trials. A pharma company running a Phase 3 oncology trial will pay $15-50 million for access to Tempus's patient matching algorithms and real-world evidence data.
The bull case is that this dataset becomes the foundational layer for AI-driven drug development — a "Google of cancer data" that commands licensing fees across the entire pharmaceutical industry. The bear case is that hospitals and health systems are increasingly building their own data capabilities and that Epic's EHR data network is a formidable competitor for patient data aggregation.
Radiology AI companies deserve separate mention as the most commercially mature segment. Nuance Communications (now part of Microsoft) has deployed AI ambient clinical documentation in 550+ hospitals, generating approximately $2 billion in annualized revenue. Rad AI, a private company, automates radiology report generation using AI trained on 50 million+ radiology reports. These businesses are growing 25-35% annually with strong unit economics.
Section 4 — Investment Framework
The healthcare AI investment framework requires balancing regulatory approval risk, data moat sustainability, and commercial adoption timelines. Three tiers of investment opportunity exist.
Tier 1 (established, profitable): Veeva Systems is the premier healthcare AI investment for risk-adjusted returns. The business is already highly profitable, the data network effects are compounding, and AI feature additions are incremental improvements to a defensible platform. At 30x forward earnings for 17% growth and 38% margins, it is the highest quality of the group.
Tier 2 (growing, path to profitability): IQVIA offers exposure to the same clinical data opportunity at lower quality but better valuation (18x). Intuitive Surgical (ISRG) is adjacent — its robotic surgery platform generates AI-analyzed procedural data that creates competitive advantages in next-generation surgical guidance systems.
Tier 3 (speculative, early-stage): Tempus AI offers the highest upside if data monetization accelerates as expected, but also the highest binary risk. The stock is appropriate as a 1-2% portfolio position for investors who understand the oncology data business model and are willing to hold through likely continued operating losses for 2-3 years.
For investors seeking concentrated healthcare AI exposure without stock selection risk, the ARK Genomic Revolution ETF (ARKG) provides diversified exposure at the cost of a 0.75% annual fee and significant portfolio volatility.
Verdict
Healthcare AI is a genuine long-term growth sector with regulatory tailwinds (accelerating FDA clearances), demographic drivers (aging populations requiring more diagnostic care), and improving AI capabilities. Veeva Systems is the highest-conviction single name — exceptional unit economics, defensible moat, and a clear AI monetization roadmap. Tempus AI is the most speculative but also most potentially transformative if its oncology data monetization thesis executes. Avoid companies that are merely "AI-washing" existing healthcare IT products without genuine clinical validation.
Data as of March 2026. Not financial advice.
— iBuidl Research Team